Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EYENYSE:GKOSNYSE:INSPNASDAQ:NARI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYENational Vision$23.90-1.1%$19.69$9.56▼$24.69$1.89B1.271.93 million shs1.08 million shsGKOSGlaukos$103.50-0.1%$95.84$77.10▼$163.71$5.91B0.82739,359 shs289,937 shsINSPInspire Medical Systems$128.39-1.8%$141.66$123.00▼$225.00$3.79B1.25551,519 shs301,417 shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.43 million shsN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYENational Vision0.00%+3.13%+14.38%+111.27%+92.24%GKOSGlaukos0.00%+2.00%+13.75%+23.77%-13.12%INSPInspire Medical Systems0.00%-3.06%-6.99%-9.26%-4.03%NARIInari Medical0.00%0.00%0.00%0.00%+59.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYENational Vision2.652 of 5 stars2.22.00.03.32.20.80.0GKOSGlaukos4.4512 of 5 stars4.41.00.04.42.71.70.6INSPInspire Medical Systems4.8514 of 5 stars4.41.00.04.83.32.51.9NARIInari MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYENational Vision 2.44Hold$18.67-21.88% DownsideGKOSGlaukos 2.75Moderate Buy$134.6730.11% UpsideINSPInspire Medical Systems 2.73Moderate Buy$211.9165.06% UpsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideCurrent Analyst Ratings BreakdownLatest EYE, GKOS, NARI, and INSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025EYENational VisionBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.005/19/2025EYENational VisionBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetMarket Perform ➝ Market Perform$13.00 ➝ $19.005/12/2025EYENational VisionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $17.005/9/2025EYENational VisionThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$13.00 ➝ $17.005/9/2025EYENational VisionCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$13.00 ➝ $21.005/8/2025EYENational VisionUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.005/8/2025EYENational VisionLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.005/8/2025EYENational VisionWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$13.00 ➝ $15.005/7/2025EYENational VisionBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Buy5/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/6/2025INSPInspire Medical SystemsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$220.00 ➝ $200.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYENational Vision$1.82B1.04$1.64 per share14.61$10.37 per share2.30GKOSGlaukos$383.48M15.42N/AN/A$13.91 per share7.44INSPInspire Medical Systems$802.80M4.72$1.71 per share75.20$23.01 per share5.58NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYENational Vision-$28.50M-$0.33N/A88.503.50-1.40%3.44%1.40%8/6/2025 (Estimated)GKOSGlaukos-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)INSPInspire Medical Systems$53.51M$2.1759.1639.871.977.92%10.00%8.68%8/5/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ALatest EYE, GKOS, NARI, and INSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025GKOSGlaukos-$0.26N/AN/AN/A$115.49 millionN/A5/7/2025Q1 2025EYENational Vision$0.32$0.34+$0.02$0.18$510.30 million$510.32 million5/5/2025Q1 2025INSPInspire Medical Systems-$0.23$0.10+$0.33$0.10$194.89 million$201.32 million4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYENational VisionN/AN/AN/AN/AN/AGKOSGlaukosN/AN/AN/AN/AN/AINSPInspire Medical SystemsN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYENational Vision0.290.540.35GKOSGlaukos0.096.495.62INSPInspire Medical SystemsN/A9.017.44NARIInari MedicalN/A1.771.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYENational VisionN/AGKOSGlaukos99.04%INSPInspire Medical Systems94.91%NARIInari Medical90.98%Insider OwnershipCompanyInsider OwnershipEYENational Vision2.70%GKOSGlaukos5.80%INSPInspire Medical Systems4.10%NARIInari Medical10.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEYENational Vision13,41179.05 million76.92 millionOptionableGKOSGlaukos78057.14 million53.83 millionOptionableINSPInspire Medical Systems1,24629.49 million28.29 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableEYE, GKOS, NARI, and INSP HeadlinesRecent News About These CompaniesFDA grants 510(k) clearance to Stryker’s total ankle systemJune 26, 2025 | medicaldevice-network.comMRoute 92 Medical Appoints Medtech Industry Veterans Mitch Hill and Lucas Buchanan to its Board of DirectorsJune 18, 2025 | finance.yahoo.comAmerican Century Small Cap Growth Fund Q1 2025 CommentaryJune 11, 2025 | seekingalpha.comThrombectomy system removes clots, improves quality of life for patients with PEMay 20, 2025 | healio.comHThe top nitinol cardiac medtech news of 2025 (so far)May 13, 2025 | medicaldesignandoutsourcing.comMStryker outlines 2025 growth targets with 8.5%-9.5% organic sales growth and $13.20-$13.45 EPSMay 2, 2025 | msn.comExpert Testimony Supporting POPR Can Be An Effective StrategyApril 21, 2025 | jdsupra.comVolta Medical Appoints Bill Hoffman as Executive Chairman of the Board of DirectorsApril 8, 2025 | finance.yahoo.com8 spine, orthopedic acquisitions in Q1March 27, 2025 | beckersspine.comBOkami Medical Announces Portfolio Expansion with the Addition of the SENDERO® MAX Delivery CatheterMarch 26, 2025 | finance.yahoo.comHow Is Inari Medical Inc. (NASDAQ:NARI) Positioned in the Medical Devices Sector?March 25, 2025 | kalkinemedia.comKIf You Could Only Hold 3 Investments for Life, Consider These (NARI)...March 10, 2025 | marketbeat.comStryker’s Inari Medical Launches Artix Thrombectomy SystemMarch 7, 2025 | evtoday.comEStryker’s Inari Medical launches Artex thrombectomy systemMarch 7, 2025 | massdevice.comInari Medical introduces thrombectomy system for arterial thrombus casesMarch 7, 2025 | msn.comInari Medical acquisition could provide Stryker with foothold in peripheral vascular marketFebruary 28, 2025 | expresshealthcare.inEWearable defibrillator maker Kestra Medical plots $150M IPOFebruary 26, 2025 | fiercebiotech.comFStryker grows cardiovascular division with Inari Medical acquisitionFebruary 24, 2025 | medicaldevice-network.comMStryker Completes Acquisition of InariFebruary 20, 2025 | evtoday.comEStryker concludes Inari Medical acquisition for $4.9bnFebruary 20, 2025 | finance.yahoo.comStryker completes Inari Medical acquisitionFebruary 20, 2025 | beckersspine.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionBy Dan Schmidt | July 2, 2025View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionIs Lululemon’s 18% Selloff Overdone? Analysts Say YesBy Gabriel Osorio-Mazilli | June 9, 2025View Is Lululemon’s 18% Selloff Overdone? Analysts Say YesToast Stock: A Fast-Growing Mid-Cap Eyeing Further UpsideBy Ryan Hasson | July 1, 2025View Toast Stock: A Fast-Growing Mid-Cap Eyeing Further UpsideRobinhood Director Sells Millions, But HOOD Stock Eyes GainsBy Gabriel Osorio-Mazilli | June 19, 2025View Robinhood Director Sells Millions, But HOOD Stock Eyes GainsCrowdStrike Eyes Breakout as Cyber Threats Boost DemandBy Chris Markoch | June 24, 2025View CrowdStrike Eyes Breakout as Cyber Threats Boost DemandEYE, GKOS, NARI, and INSP Company DescriptionsNational Vision NASDAQ:EYE$23.90 -0.27 (-1.10%) Closing price 07/3/2025 03:22 PM EasternExtended Trading$23.60 -0.30 (-1.26%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.Glaukos NYSE:GKOS$103.50 -0.13 (-0.13%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$103.42 -0.08 (-0.07%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Inspire Medical Systems NYSE:INSP$128.38 -2.34 (-1.79%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$128.38 0.00 (0.00%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
